Showing 4271-4280 of 10629 results for "".
Predicting Outcomes in IBD with Fecal Biomarkers
https://reachmd.com/programs/gi-insights/predicting-outcomes-in-ibd-with-fecal-biomarkers/32328/Read about recent findings on fecal biomarkers that can help predict complications in patients with inflammatory bowel disease.Using Transepidermal Water Loss to Guide Oral Food Challenges
https://reachmd.com/programs/Audioabstracts/transepidermal-water-loss-guide-oral-food-challenges/54217/Can real-time transepidermal water loss (TEWL) monitoring reduce the risk of anaphylaxis during oral food challenges in young children with peanut allergy? A pilot trial suggests it may. TEWL-guided stopping significantly lowered anaphylaxis rates and reaction severity without delaying treatment. ThDECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
https://reachmd.com/clinical-practice/cardiology/decaf-trial-does-eliminating-coffee-reduce-atrial-fibrillation-recurrence-in-symptomatic-patients/48690/Does caffeine abstinence affect atrial fibrillation recurrence in patients with symptomatic AF? Tune in for a review of the DECAF trial results!Managing Psoriasis Flare-Ups: The Influence of Ultra-Processed Foods
https://reachmd.com/programs/spotlight-psoriasis/managing-psoriasis-flare-ups-the-influence-of-ultra-processed-foods/32444/Ultra-processed foods may exacerbate flare-ups in patients with psoriasis. Read about a recent study and its findings on this potential connection.DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
https://reachmd.com/clinical-practice/cardiology/dare-af-trial-dapagliflozin-to-reduce-af-burden-after-catheter-ablation-in-patients-without-diabetes-or-heart-failure/48682/Can dapagliflozin reduce AF burden in your patients without diabetes or heart failure after ablation? Our expert is breaking down the DARE-AF trial results!COVID-19 Reflections: How to Address Vaccine Messaging and Public Health Challenges
https://reachmd.com/programs/clinicians-roundtable/covid-19-reflections-how-to-address-vaccine-messaging-and-public-health-challenges/29091/Here to share his perspective on how we can address the public health challenges stemming from the COVID-19 pandemic is Dr. Aslam Khan.Tracking Immune Activity in Severe Alopecia Areata
https://reachmd.com/programs/dermconsult/immune-activity-severe-alopecia-areata/49022/Sjögren’s-Related Dry Eye: Examining Targeted Treatment Strategies
https://reachmd.com/programs/living-rheum/sjogrens-related-dry-eye-examining-targeted-treatment-strategies/36339/Sjögren’s-related dry eye requires intensive management, often combining lubrication with anti-inflammatory therapies and other interventions to reduce symptoms and improve quality of life. Join Dr. Michelle Hessen, Assistant Professor of Ophthalmology at the Wilmer Eye Institute and a member of theNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
https://reachmd.com/programs/frontlines-prostate-cancer/new-frontiers-in-the-imaging-and-treatment-of-advanced-prostate-cancer/32221/From PSMA imaging to precision medicine strategies based on molecular drivers, novel diagnostics and therapies are reshaping the way we care for men with advanced prostate cancer. But despite these advancements, certain challenges and unmet needs remain. Joining Dr. Wayne Kuang to talk about these eEvolving Treatment Patterns in mHSPC: Shifts in ARPi and Triplet Use
https://reachmd.com/programs/frontlines-prostate-cancer/evolving-treatment-patterns-in-mhspc-shifts-in-arpi-and-triplet-use/32218/Based on a recent analysis of over 10,000 patients from the Komodo claims database, there’s currently a shift toward using combination therapies—particularly AR pathway inhibitors (ARPis) with or without docetaxel—to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC). Here to d